Abstract
The use of imatinib mesylate (Glivec) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in whom imatinib treatment results in the development of toxic complications is small. Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy.
MeSH terms
-
Aged
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Diagnosis, Differential
-
Female
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Lung Diseases, Interstitial / chemically induced*
-
Lung Diseases, Interstitial / diagnostic imaging
-
Piperazines / adverse effects*
-
Piperazines / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Pyrimidines / adverse effects*
-
Pyrimidines / therapeutic use
-
Tomography, X-Ray Computed
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases